Pulmonx Q1 revenue falls 9% to $20.6 million; net loss narrows to $13.7 million
Pulmonx reported first-quarter 2026 revenue of $20.6 million, down 9% from $22.5 million a year earlier, driven by a lack of China sales while it awaits renewal of its registration certificate. The net loss narrowed to $13.7 million, or $0.33 per share, from $14.4 million, or $0.36 per share, and the company kept its full-year 2026 revenue outlook of $90 million to $92 million unchanged.
Key points
- Worldwide revenue was $20.6 million, down 9% year over year and down 12% on a constant currency basis.
- International revenue fell 12% to $7.3 million, while international revenue excluding China grew 22%.
- Gross margin rose to 78% from 73%, and the net loss narrowed to $13.7 million, or $0.33 per share.
- Full-year 2026 revenue guidance of $90 million to $92 million was reiterated, and cash and equivalents were $61.6 million as of March 31, 2026.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.